Login to Your Account



Other News To Note


Wednesday, May 23, 2012
• Cytos Biotechnology Ltd., of Zurich, Switzerland, said it completed a CHF23.75 million (US$25.2 million) equity investment. The financing is part of a planned CHF37 million debt and equity deal to be provided by an international syndicate of investors, including venBio, Abingworth, Aisling Capital and Amgen. Cytos intends to use the proceeds primarily to conduct a Phase IIb study of CYT003 in allergic asthma.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription